ADXS


Stock Update (NASDAQ:ADXS): Advaxis, Inc. Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced dose administration for the first patient in the first stage of …

Sell-Side Analysts Weigh In on Two Small Cap Biotechs: Advaxis, Inc. (ADXS) and Keryx Biopharmaceuticals (KERX)

Healthcare analysts at sell-side firms FBR and Brean Capital were out today with some commentary on small-cap biotech companies Advaxis, Inc. (NASDAQ:ADXS) and Keryx Biopharmaceuticals (NASDAQ:KERX).

Stock Update (NASDAQ:ADXS): FDA Grants Advaxis, Inc. Fast Track Designation for ADXS-HER2

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track …

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Combination Trial with Merck Completes First Two Dose-Escalation Cohorts

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck & Co.

Stock Update (NASDAQ:ADXS): Advaxis, Inc. Combination Trial With MedImmune Completes First Dose-Escalation Cohort

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced their combination study with MedImmune, the global biologics research and development …

Monday Morning’s Market Insights: Valeant Pharmaceuticals Intl Inc (VRX), Advaxis, Inc. (ADXS), Seadrill Ltd (SDRL), Starwood Hotels & Resorts Worldwide Inc (HOT)

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was halted at 8:15 Eastern Time and is now down 5% in pre-market trading after news that CEO Micheal …

Stock Update (NASDAQ:ADXS): Survival Results with Advaxis, Inc. HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research

(NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma (OSA) was …

Stock Update (NASDAQ:ADXS): Advaxis, Inc.’s Axalimogene Filolisbac to be Developed and Commercialized in Latin America With Stendhal

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a co-development and commercialization agreement with …

Company Update (NASDAQ:ADXS): Advaxis, Inc. Appoints Dr. Bradley Monk as Lead Cervical Cancer Advisor

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the appointment of Bradley J.

Company Update (NASDAQ:ADXS): Advaxis, Inc. Expands Intellectual Property for Lm Technology™ Platform

Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, announced that it has added two more patents to its growing patent portfolio.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts